Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SOL 116

Next Previous
Drug Profile

SOL 116

Alternative Names: anti-BSSL; Anti-BSSL antibody - Lipum; Bile salt-stimulated lipase targeting monoclonal antibody - Lipum; SOL-116

Latest Information Update: 05 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lipum
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Sterol esterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Juvenile rheumatoid arthritis; Psoriatic arthritis; Systemic lupus erythematosus
  • Research Cancer

Most Recent Events

  • 05 Oct 2026 SOL 116 is still in phase I trials for Rheumatoid arthritis in Netherlands (SC) (Lipum pipeline, September 2026)
  • 29 Sep 2026 Clairvoyant Diagnostics and Lipum enters into an agreement for the evaluation of biomarker strategy to support the future clinical development of SOL 116 in chronic inflammatory diseases
  • 28 Sep 2026 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Netherlands (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top